Indivior Pharmaceuticals Inc beat EPS estimates 92% of the time across 13 reported quarters (12 beats, 1 misses), averaging +42.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.97 | $1.15 | +18.6% | Beat | |
| Q1 FY26 | $0.64 | $0.96 | +50.0% | Beat | |
| Q4 FY25 | $0.65 | $0.82 | +26.1% | Beat | Q4 FY25 call |
| Q3 FY25 | $0.38 | $0.72 | +89.5% | Beat | |
| Q2 FY25 | $0.26 | $0.51 | +96.2% | Beat | |
| Q1 FY25 | $0.22 | $0.41 | +86.4% | Beat | |
| Q4 FY24 | $0.32 | $0.32 | +0.0% | Beat | |
| Q3 FY24 | $0.39 | $0.54 | +38.5% | Beat | |
| Q2 FY24 | $0.40 | $0.44 | +10.0% | Beat | |
| Q1 FY24 | $0.38 | $0.37 | -2.6% | Miss | |
| Q4 FY23 | $0.28 | $0.43 | +53.6% | Beat | |
| Q3 FY23 | $0.30 | $0.34 | +13.3% | Beat |
Back to INDV overview · INDV holders · INDV KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.